Full metadata record
DC FieldValueLanguage
dc.creatorLasa-Saracibar, B. (Beatriz)-
dc.creatorEstella-Hermoso-de-Mendoza, A. (Ander)-
dc.creatorMollinedo, F. (Faustino)-
dc.creatorOdero, M.D. (Maria Dolores)-
dc.creatorBlanco-Prieto, M.J. (María José)-
dc.date.accessioned2014-03-03T15:39:09Z-
dc.date.available2014-03-03T15:39:09Z-
dc.date.issued2013-
dc.identifier.citationLasa-Saracíbar B, Estella-Hermoso de Mendoza A, Mollinedo F, Odero MD, Blanco-Príeto MJ. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines. Cancer Lett 2013 7/1;334(2):302-310es_ES
dc.identifier.issn0304-3835-
dc.identifier.urihttp://hdl.handle.net/10171/35342-
dc.description.abstractAlthough current therapies have improved leukemia survival rates, adverse drug effects and relapse are frequent. Encapsulation of edelfosine (ET) in lipid nanoparticles (LN) improves its oral bioavailability and decreases its toxicity. Here we evaluated the efficacy of ET-LN in myeloid leukemia cell lines. Drug-loaded LN were as effective as free ET in sensitive leukemia cell lines. Moreover, the encapsulated drug overcame the resistance of the K562 cell line to the drug. LN containing ET might be used as a promising drug delivery system in leukemia due to their capacity to overcome the in vivo pitfalls of the free drug and their efficacy in vitro in leukemia cell lines.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAlkyl-lysophospholipidses_ES
dc.subjectEdelfosinees_ES
dc.subjectLipid nanoparticleses_ES
dc.subjectLeukemiaes_ES
dc.titleEdelfosine lipid nanosystems overcome drug resistance in leukemic cell lineses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.canlet.2013.01.018-

Files in This Item:
File: 
Edelfosine.pdf
Description: 
Size: 
1,05 MB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.